Net debt/EBITDA společnosti Aerie Pharmaceuticals Inc
Jaká je hodnota metriky Net debt/EBITDA společnosti Aerie Pharmaceuticals Inc?
Hodnota metriky Net debt/EBITDA společnosti Aerie Pharmaceuticals Inc je -88.65
Jaká je definice metriky Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Aerie Pharmaceuticals Inc
Čemu se věnuje společnost Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou net debt/ebitda podobnou společnosti Aerie Pharmaceuticals Inc
- Hodnota metriky Net debt/EBITDA společnosti General Cannabis je -89.75
- Hodnota metriky Net debt/EBITDA společnosti Kanadario Gold je -89.59
- Hodnota metriky Net debt/EBITDA společnosti Crown International je -89.55
- Hodnota metriky Net debt/EBITDA společnosti Calamp je -89.43
- Hodnota metriky Net debt/EBITDA společnosti Seachange International je -89.10
- Hodnota metriky Net debt/EBITDA společnosti Oportun Corp je -88.78
- Hodnota metriky Net debt/EBITDA společnosti Aerie Pharmaceuticals Inc je -88.65
- Hodnota metriky Net debt/EBITDA společnosti Suncity je -88.58
- Hodnota metriky Net debt/EBITDA společnosti Tang Palace (China) je -88.56
- Hodnota metriky Net debt/EBITDA společnosti Miricor Enterprises je -88.51
- Hodnota metriky Net debt/EBITDA společnosti Agripower France SA je -88.19
- Hodnota metriky Net debt/EBITDA společnosti Wah Wo je -88.08
- Hodnota metriky Net debt/EBITDA společnosti Safestay plc je -87.92